Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus

OBJECTIVES: We have reported previously that Belimumab, a human monoclonal antibody that inhibits B-cell activating factor(BAFF) could be an effective and safe option to treat Neuropsychiatric manifestations of SLE (NPSLE). To avoid inadequate efficacy of Belimumab and significant adverse events of...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Hao, Zhang, Xiao-ying, Yang, Hui-dan, Yu, Zhen, Yan, Cheng-lan, Gao, Chong, Wen, Hong-yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376229/
https://www.ncbi.nlm.nih.gov/pubmed/35979351
http://dx.doi.org/10.3389/fimmu.2022.911730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376229/
https://www.ncbi.nlm.nih.gov/pubmed/35979351
http://dx.doi.org/10.3389/fimmu.2022.911730

Ejemplares similares